AyuVis Research

AyuVis Research, founded in 2016, is a private, preclinical-stage biotech developing first-in-class small molecule immunotherapies that modulate white blood cells to address severe inflammatory and infectious diseases. Its lead programs target unmet needs in respiratory complications like BPD and PAP, with a unique mechanism designed to avoid drug resistance and immunosuppression. The company has secured non-dilutive NIH grant funding, won several entrepreneurial awards, and is preparing for first-in-human clinical trials. Led by founder and CEO Dr. Suchismita Acharya, AyuVis leverages a platform with potential applications across multiple critical care indications.

Platform of novel small molecule immunotherapies that modulate innate immune cells (e.g., white blood cells) to fight infection and resolve inflammation without causing immunosuppression or contributing to multi-drug resistance.

The ARDS and immune modulation space is competitive, with numerous biopharma companies investigating anti-inflammatory and immunomodulatory agents. AyuVis differentiates itself with a small molecule approach targeting innate immunity, aiming for a balance between anti-infective and anti-inflammatory effects, a niche with fewer established players compared to cytokine-targeting biologics.